US Patent

US8293284 — Methods of reducing the risk of occurrence of pulmonary edema in term or near-term neonates in need of treatment with inhaled nitric oxide

Method of Use · Assigned to INO Therapeutics LLC · Expires 2029-06-30 · 3y remaining

Vulnerability score 73/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of reducing the risk or preventing pulmonary edema in term or near-term neonates treated with inhaled nitric oxide.

USPTO Abstract

The invention relates methods of reducing the risk or preventing the occurrence of an adverse event (AE) or a serious adverse event (SAE) associated with a medical treatment comprising inhalation of nitric oxide.

Drugs covered by this patent

Inomax (NITRIC OXIDE) · Vero Biotech Inc

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1286`	—	Inomax
`U-1286`	—	Inomax

Patent Metadata

Patent number: US8293284
Jurisdiction: US
Classification: Method of Use
Expires: 2029-06-30
Drug substance claim: No
Drug product claim: No
Assignee: INO Therapeutics LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.